Alebund Pharmaceuticals gets FDA IND clearance for AP308 in IgA nephropathy
FDA clears Alebund’s AP308 for human testing in IgA nephropathy, taking a novel IgA-cleaving strategy beyond promising preclinical data.
Pharma & Biotech